A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Immunogenicity of STSP-0902 in Healthy Subjects
Latest Information Update: 12 Jun 2025
At a glance
- Drugs STSP 0902 (Primary)
- Indications Asthenozoospermia; Neurotrophic keratopathy; Oligospermia
- Focus Adverse reactions
- Sponsors Staidson Beijing BioPharmaceuticals
Most Recent Events
- 22 May 2025 Status changed from not yet recruiting to recruiting.
- 06 May 2025 New trial record